Replimune Group, Inc.
Replimune Group, Inc.（REPL）股东结构
基于 13F 申报与流通股数据，展示机构、内部人与公众持股结构；下方为前十大机构、机构动向与内部人交易。
SEC 13F · FMP · REPL · 截至 2025年3月31日
股东结构概览
170
机构持有人数
▲ 10 vs Q4
$799.31M
机构持仓总市值
▼ $143.91M vs Q4
82.57M
总流通股
freeFloat 92.33%
81.98M
13F 申报持股数
▲ 4.09M vs Q4
机构持仓% = 13F 持股数 ÷ 总流通股。内部人% = 100 − 自由流通率。散户% = 自由流通率 − 机构%。数据来源：FMP /symbol-positions-summary + /shares-float + SEC EDGAR。
前10大机构持仓
REPL 最大股东 · 机构持仓
Q1 2025 · SEC 13F
显示前 10 家
| 机构 | 持股数 | 占比 | 权重 | 市值 | 申报日 | 变动 |
|---|---|---|---|---|---|---|
BAKER BROS. ADVISORS LP biological products, (no diagnostic substances) | 11.05M | 13.23% | 13.23% | $107.69B | May 15, 2025 | — held |
PRICE T ROWE ASSOCIATES INC /MD/ biological products, (no diagnostic substances) | 10.85M | 13.00% | 13.00% | $105.83B | May 14, 2025 | ▼ 109.1K |
BLACKROCK, INC. biological products, (no diagnostic substances) | 6.06M | 7.26% | 7.26% | $59.10B | May 2, 2025 | ▲ 495.5K |
REDMILE GROUP, LLC biological products, (no diagnostic substances) | 4.90M | 5.87% | 5.87% | $47.76B | May 15, 2025 | ▼ 7.0K |
FCPM III SERVICES B.V. biological products, (no diagnostic substances) | 3.91M | 4.85% | 4.85% | $38.12B | May 15, 2025 | ▼ 61.0K |
VANGUARD GROUP INC biological products, (no diagnostic substances) | 3.83M | 4.59% | 4.59% | $37.37B | May 9, 2025 | ▲ 237.2K |
TANG CAPITAL MANAGEMENT LLC biological products, (no diagnostic substances) | 2.90M | 3.47% | 3.47% | $28.27B | May 15, 2025 | ▲ 200.0K |
MARSHALL WACE, LLP biological products, (no diagnostic substances) | 2.49M | 2.98% | 2.98% | $24.25B | May 15, 2025 | ▲ 1.59M |
SOFINNOVA INVESTMENTS, INC. biological products, (no diagnostic substances) | 2.48M | 2.97% | 2.97% | $24.18B | May 15, 2025 | ▼ 669.6K |
STATE STREET CORP biological products, (no diagnostic substances) | 2.40M | 2.87% | 2.87% | $23.38B | May 15, 2025 | ▲ 194.0K |
数据来源：SEC 13F 申报文件。变动标识：isNew / isSoldOut / changeInSharesNumber。
机构仓位变动
Q1 2025 对比上季度
Q1 2025
27
增持
+5.46M 股5
新建仓
首次建仓13
减持
−1.70M 股0
清仓
完全退出净股数变化（前50家）
+3.76M
+5.46M / −1.70M
净新增持仓人
+19
新建 5 个 / 退出 0 个
基于前50家最大机构持仓统计，全市场实际数量可能不同。
内幕交易买卖情绪
REPL 内幕交易记录
数据来源：SEC Form 4
近期内部人员以卖出为主。 卖出可能源于预定的 10b5-1 计划，不代表负面展望。
19
买入笔数
8
卖出笔数
2.38
买卖比
$0M
卖出总金额
最近内幕交易记录
最近10条 · 仅普通股
| 姓名 · 职位 | 日期 | 类型 | 股数 | 价格 | 金额 | 交易后持股 | 申报 |
|---|---|---|---|---|---|---|---|
Sarchi Christopher Chief Commercial Officer | Jun 1, 2026 | Sale | 12,000 | $9.24 | $110.9K | 181.0K | Form 4 ↗ |
Xynos Konstantinos Chief Medical Officer | May 18, 2026 | Sale | 14,023 | $5.08 | $71.2K | 235.7K | Form 4 ↗ |
Schwendenman Andrew Chief Accounting Officer | May 18, 2026 | Sale | 7,894 | $5.08 | $40.1K | 107.1K | Form 4 ↗ |
Sarchi Christopher Chief Commercial Officer | May 18, 2026 | Sale | 8,626 | $5.08 | $43.8K | 193.0K | Form 4 ↗ |
Astley-Sparke Philip director | May 18, 2026 | Sale | 17,657 | $5.08 | $89.7K | 1.41M | Form 4 ↗ |
Patel Sushil Chief Executive Officer | May 18, 2026 | Sale | 37,324 | $5.08 | $189.6K | 747.5K | Form 4 ↗ |
Hill Emily Luisa Chief Financial Officer | May 18, 2026 | Sale | 7,812 | $5.08 | $39.7K | 236.6K | Form 4 ↗ |
BAKER BROS. ADVISORS LP
| Apr 1, 2026 | Award | 44,500 | $7.61 | $338.6K | 44.5K | Form 4 ↗ |
Sarchi Christopher Chief Commercial Officer | Apr 1, 2026 | Award | 50,000 | — | — | 201.6K | Form 4 ↗ |
Sarchi Christopher Chief Commercial Officer | Apr 1, 2026 | Award | 75,000 | $7.61 | $570.8K | 75.0K | Form 4 ↗ |
数据来源：SEC Form 4。买卖方向：acquisitionOrDisposition A=买入，D=卖出。已排除 RSU 归属（M-Exempt）。
关于机构与内部人持股结构
Replimune Group, Inc.（REPL）主要由机构投资者持有，机构持股比例约为 99.3%。公司内部人员持股约 7.67%，散户及公众持股约占剩余的 0.00%。
Replimune Group, Inc. 最大机构股东为 BAKER BROS. ADVISORS LP，截至 March 31, 2025 持有约 11.05 million 股，占总流通股的 13.23%。
目前共有 170 家机构持有 REPL 股票，合计持仓市值约 $799,309,539，数据来源为最新 SEC 13F 申报。
常见问题
REPL ownershipReplimune Group, Inc.（REPL）主要由机构投资者持有，机构持股约 99.3%。最大股东为 BAKER BROS. ADVISORS LP，持股比例 13.23%。内部人员持股约 7.67%。数据来源 SEC Form 13F，截至 March 31, 2025。